Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1612
This examiner grants 59% of resolved cases
Lucy Minyu Tien serves in Tech Center 1600 and Art Unit 1612. The examiner has an allowance rate of 59.3% based on 86 resolved cases. The median days to allowance is 1041, which is a timeline for reaching a grant. These figures suggest an environment where about 59.3% of cases are successful.
The interview lift is 39.2%. This suggests that interviews are effective for this examiner, increasing the probability of success over the 59.3% baseline. For practitioners, the 39.2% lift indicates that direct communication is a strategy for overcoming rejections. Given the 1041-day median pendency, an interview may also be a tool for moving the case toward a grant. With 86 resolved cases, the data shows a trend where verbal communication is effective. Prioritizing an interview is a strategy for success in Art Unit 1612 to leverage the 39.2% lift.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18041973 | DOPA MODIFIED GELATIN FOR WOUND HEALING AND METHODS OF MAKING THE SAME | Non-Final OA | BOSTON SCIENTIFIC SCIMED, INC. |
| 18711649 | BIOCIDE COMPOSITIONS | Non-Final OA | BASF SE |
| 18278907 | MICRONEEDLE COMPOSITIONS AND METHODS OF DELIVERY USING THE SAME | Non-Final OA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 18549497 | CHIRAL N-(1,3,4-OXADIAZOLE-2-YL)PHENYL CARBOXYLIC ACID AMIDES AND THEIR USE AS HERBICIDES | Final Rejection | Bayer Aktiengesellschaft |
| 18529500 | USE OF A COMPOSITE MATERIAL | Final Rejection | Heraeus Medical GmbH |
| 18680901 | COMPOSITIONS AND METHODS FOR CLEANSING KERATIN MATERIALS | Non-Final OA | L'Oreal |
| 18713833 | AQUEOUS CARE AND/OR MAKEUP COMPOSITION COMPRISING A FATTY ACID MONOESTER, A NEUTRALIZED ANIONIC SURFACTANT, A VP/EICOSENE COPOLYMER AND A DYESTUFF | Non-Final OA | L'OREAL |
| 18713830 | AQUEOUS CARE AND/OR MAKEUP COMPOSITION COMPRISING A FATTY ACID MONOESTER, A NEUTRALIZED ANIONIC SURFACTANT, A VP/EICOSENE COPOLYMER, A SEMICRYSTALLINE POLYMER AND A LATEX | Non-Final OA | L'OREAL |
| 17686880 | PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL DOSAGE FORM, PROCESS FOR THEIR PREPARATION, METHODS FOR TREATING AND USES THEREOF | Final Rejection | Boehringer Ingelheim International GmbH |
| 18713856 | HAIR CLEANSING COMPOSITION | Final Rejection | KAO CORPORATION |
| 18690286 | POROUS TITANIUM ALLOY STRUCTURE WITH A SILVER COATING HAVING OSTEOCOMPATIBILITY AND ANTIMICROBIAL PROPERTIES | Final Rejection | WALDEMAR LINK GMBH & CO. KG |
| 18301004 | Compositions Comprising Lipophilic Compounds and One or More (Bio)-Alkanediols | Non-Final OA | Symrise AG |
| 18009284 | Compositions Comprising Lipophilic Compounds and One or More (Bio)-Alkanediols | Final Rejection | Symrise AG |
| 18285570 | SILICA-BASED FORMULATIONS OF THERAPEUTIC OLIOGPEPTIDES AND PEPTIDOMIMETICS | Final Rejection | Stealth BioTherapeutics Inc. |
| 18556513 | SILICON PARTICLES FOR DRUG DELIVERY | Final Rejection | NACAMED AS |
| 18373612 | TOPICAL DELIVERY COMPOSITIONS COMPRISING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | Non-Final OA | Andros Pharmaceuticals Co., LTD. |
| 18329496 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | Non-Final OA | Xygenyx Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy